Lenz & Staehelin advised the underwriters on ADC’s sale of 13.4 million shares of its common stock and pre-funded warrants to purchase 8.1 million shares of its common stock in an underwritten offering for gross proceeds
Tags :ADC
Lenz & Staehelin has advised investment bank Jefferies as underwriter in the public offering of shares of the Lausanne based ADC Therapeutics, a commercial-stage biotechnology company helping to improve the lives of those affected by
ADC Therapeutics, a commercial-stage biotechnology company headquartered in Lausanne, announced the pricing of an underwritten offering of 12 m ADCT shares currently owned by A.T. Holdings II, an affiliate of Auven Therapeutics Holding, at a
